ReviewVeterinary research communications2025
Monoclonal antibodies in veterinary antiviral immunotherapy: technologies, applications and challenges.
Review in Veterinary research communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monoclonal antibodies (mAbs) are highly specific immunoglobulins that bind viral antigens with high affinity, making them valuable tools for diagnosis and targeted antiviral therapy in veterinary medicine. While mAbs are widely used in human healthcare, their application in veterinary medicine is limited. Only a few licensed products are available for animal health, and most candidates are in experimental or pre-clinical stages. This review provides a comprehensive overview of neutralizing mAbs targeting veterinary viral pathogens, including significant advances in production technologies and associated challenges. These innovations aim to reduce immunogenicity, improve efficacy, and expand the range of treatable diseases in companion animals, livestock, and wildlife. Despite these advances, high production costs, logistical constraints, and viral escape through mutation remain significant challenges to clinical implementation. If technological progress is integrated with strategies for overcoming these limitations, antiviral mAbs have the potential to become essential components of veterinary medicine. Their incorporation into a One Health framework could also enhance preparedness for emerging and zoonotic viral threats.
Indexed as
Identifiers
41123752What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.